CervoMedCRVO
Market Cap: $145M
About: CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
900% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 2
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
90% more funds holding
Funds holding: 20 [Q1] → 38 (+18) [Q2]
1.03% more ownership
Funds ownership: 40.75% [Q1] → 41.78% (+1.03%) [Q2]
1% more capital invested
Capital invested by funds: $58.6M [Q1] → $59M (+$426K) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Chardan Capital Daniil Gataulin 33% 1-year accuracy 6 / 18 met price target | 212%upside $55 | Buy Initiated | 18 Sept 2024 |
Morgan Stanley Jeffrey Hung 50% 1-year accuracy 10 / 20 met price target | 99%upside $35 | Overweight Initiated | 26 Jul 2024 |
Canaccord Genuity Sumant Kulkarni 40% 1-year accuracy 8 / 20 met price target | 269%upside $65 | Buy Maintained | 25 Jul 2024 |
Brookline Capital Tyler Bussian 100% 1-year accuracy 3 / 3 met price target | 257%upside $63 | Buy Initiated | 8 Jul 2024 |